The objectives of this study were to characterize patterns of care and to identify predictors for adjuvant therapy in elderly patients with glioblastoma in the modern era. METHODS. The National Cancer Data Base was queried for patients aged 70 years and older with glioblastoma diagnosed from January 1, 2004 through December 31, 2012. Multinomial logistic regression was used to identify predictors for receiving adjuvant therapy. Survival outcomes were estimated using the Kaplan-Meier method and were analyzed using Cox regression models and the log-rank test. RESULTS: In total, 14,886 patients were identified. Of these, 8214 patients (55.2%) received combined-modality therapy with chemotherapy and radiation (CRT), 3955 (26.6%) received no adjuvant therapy, 2065 (13.9%) received radiation therapy (RT) alone, and 652 (4.4%) received chemotherapy (CT) alone after undergoing resection. The receipt of CRT increased in frequency over the study interval, from 40.3% in 2004 to 59.8% in 2012. Younger patients (ages 70-75 years) were more likely to receive CRT than no adjuvant therapy (P <.0001 for all other age groups) or adjuvant RT alone (P <.0001 for all other age groups). Combined-modality therapy with adjuvant CRT produced improved survival outcomes, and the highest median overall survival was 9.2 months. CONCLUSIONS: In this analysis of elderly patients who had glioblastoma diagnosed from 2004 through 2012, a significant increase in the receipt of combined-modality therapy was observed. Combined-modality treatment produces improved survival outcomes and should be considered as adjuvant treatment for carefully selected elderly patients.
INTRODUCTION
Glioblastoma (GBM) is the most common malignant primary brain tumor, comprising nearly one-half of all diagnosed adult cases. 1 Glioblastoma is most often diagnosed in elderly patients, and more than 6000 new diagnoses of GBM in adults aged >65 years are estimated in the United States during 2016. 2 Although the incidence of GBM increases with age, 3 older patients may be less likely to receive adjuvant therapy. 4, 5 Elderly patients have frequently been excluded from clinical trials, 6 and those studies that do examine this population have demonstrated suboptimal survival outcomes. 4, 5, 7 Determining the ideal adjuvant treatment for elderly patients is further complicated by multiple treatment options. Chemotherapy (CT) alone, 8, 9 radiotherapy (RT) alone, 10 and combined-modality therapy using CT and RT (CRT), 11, 12 have all produced improved outcomes in select elderly patients. Age is just 1 of many factors clinicians may consider when choosing therapy for patients with GBM. 13 Because quality data have demonstrated improvements in the outcomes of elderly patients with the receipt of adjuvant therapy, 10 additional factors besides age, such as performance status and extent of tumor resection, are needed to allow for more directed selection of patients who would benefit from adjuvant therapy. Identifying patterns of care for elderly patients is not only helpful to better define the current clinical practice when many different treatment approaches are used, but it may demonstrate avenues for improving outcomes in this vulnerable population.
With multiple adjuvant strategies demonstrating benefit, significant heterogeneity may exist in the selection of adjuvant treatment for elderly patients with GBM, and national patterns of care in the United States are not well understood. We examined the National Cancer Data Base (NCDB) to analyze patterns of practice and outcomes among elderly patients with newly diagnosed GBM and to identify factors predictive for improved outcomes, enabling more optimal selection of adjuvant therapy for this population.
MATERIALS AND METHODS

Patients
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. A large national database containing approximately 70% of all malignancies diagnosed in the United States, 14 the NCDB captures hospital-level data from more than 1500 hospitals. Patient demographic characteristics, tumor characteristics, and overall survival (OS) outcomes are collected. In addition, characteristics of the initial treatment course, including surgery, RT, and CT, are recorded. This study was deemed exempt by our institutional review board.
The NCDB brain data set of adult aged 18 years and older was queried for patients aged >70 years with newly diagnosed GBM who had complete patient demographic characteristics and surgical, RT, and CT data sets. Selected patients were limited to those diagnosed from 2004 through 2012 (Fig. 1) . Patients who lacked surgical confirmation or who died within 30 days of undergoing surgical resection were excluded. Patients who started receiving adjuvant therapy >180 days from resection also were excluded from this study.
Treatment facilities were sorted into 4 categories. Academic facilities included all programs treating 500 or more newly diagnosed cases of carcinoma per year while training postgraduate medical residents in at least 4 program areas, including internal medicine and surgery.
Community facilities included both facilities treating more than 100 but less than 500 diagnosed cases of carcinoma per year and comprehensive community cancer facilities treating 500 or more newly diagnosed cancer cases yearly, with training postgraduate medical residents optional. Integrated facilities consisted of networks of multiple centers that included at least 1 hospital, with no minimum caseload and training residents optional. The other category included Veterans Affair cancer programs and nonhospital-based, free-standing cancer center programs offering at least 1 cancer-related treatment modality.
Although patients may have received treatment at different facilities as part of their primary course of therapy, patients who were diagnosed or receiving treatment, including surgical resection, at a facility reporting to the NCDB were followed by a hospital registrar from the reporting facility and were required to report information regarding adjuvant therapy and survival regardless of whether the patient received part of their care at nonCommission on Cancer facility. Patients who underwent surgical resection at a tertiary center but received part of their care at a different facility were followed by a hospital registrar from the tertiary center, who was required to record and report information regarding any subsequent or prior care received by the patient at the other facility to the NCDB. adult GBM, 6 demographics for our select population demonstrated a decrease in the frequency with which elderly patients received adjuvant RT alone and a concordant increase in the receipt of adjuvant combined CT and RT (CRT) from 2004 through 2008; therefore, patients who were diagnosed in 2004 were included.
Statistical Analysis
For the current analyses, patients were grouped into treatment cohorts, including adjuvant RT alone, adjuvant CT alone, adjuvant CRT, and no adjuvant therapy. The cumulative dose of RT and the number of RT fractions were not used as exclusion criteria, except in those analyses using RT dosing information. Common dosage schedules from the literature were considered, and the proportion of patients within each was assessed. Multivariate, multinomial logistic regression analysis 15 of patient demographic characteristics, including age, Charlson-Deyo comorbidity score, education level, income level, insurance status, and race, as well as treatment facility type was used to identify predictors of receiving adjuvant CRT, CT alone, RT (RT alone or as part of CRT), or no adjuvant therapy. Multivariate logistic regression was used to identify predictors for receiving adjuvant CRT versus RT alone using patients who had complete RT dosing information.
Survival outcomes were estimated using the KaplanMeier method. Cox regression modeling and the log-rank test were used to detect differences in survival outcomes between treatment paradigms. The proportional-hazards assumption was tested for all covariates in the Cox regression model by considering the correlation between the survival time and the Schoenfeld residuals. 16 Covariates with correlations greater than 0.05 were assumed to violate the proportional-hazards assumption. The Cox regression model was stratified by treatment regimen, and other covariates were identified that violated the proportional-hazards assumption. P values < a 5 .05 were considered significant. All analyses were performed using the R statistical software (version 3.3.1; R Project for Statistical Computing, Vienna, Austria).
RESULTS
Patient Population
We identified 14,866 adults aged 70 years who had GBM diagnosed from 2004 through 2012 in the NCDB data set (Supporting Table 1 ; see online supporting information). The median age of our population was 76 years (range, from 70 to 90 years) and 54.5% of patients were men. Most patients in our cohort (n 5 8214; 55.2%) received combined-modality therapy with CRT.
However, many patients received alternate adjuvant strategies, including 3955 patients (26.6%) who received no adjuvant therapy, 2095 (13.9%) who received RT alone, and 652 (4.4%) who received CT alone after undergoing resection.
Factors Associated With Adjuvant Therapy
The factors associated with each of the 3 treatment paradigms were identified, with no adjuvant therapy serving as the reference group (Table 1) . The adjusted odds ratio (OR) of receiving each of the 3 treatment paradigms relative to no adjuvant therapy over the study interval is depicted in Figure 2 .
CT Hispanic ethnicity, lower Charlson/Deyo comorbidity score, and treatment at a community facility were independently associated with an increased likelihood of receiving adjuvant CT alone compared with no adjuvant therapy ( Table 1) . Patients who were treated at community treatment facilities were more likely to receive adjuvant CT (OR, 1.43; C95% confidence interval [CI], 1.19-1.72) than no adjuvant therapy compared with patients who were treated at academic facilities.
When stratified by age, patients ages 75 to 80, 80 to 85, 85 to 90, and 90 years (OR, 0.87-0.44; P < .0380 for all) were all significantly less likely to receive adjuvant CT than no therapy compared with the reference group (patients ages 70-75 years). Each age subgroup was less likely to receive adjuvant CT than the immediately preceding age subgroup.
RT
Black race (compared with white race), a shorter distance to the treatment facility, treatment at a community facility (compared with an academic facility), a lower Charlson/ Deyo comorbidity score, and earlier year of diagnosis were associated with an increased likelihood of receiving adjuvant RT alone versus no adjuvant therapy (Table 1) . Patients ages 70 to 75 years (reference group) were more likely to receive adjuvant RT alone than no adjuvant therapy compared with patients ages 85 to 90 years (OR, 0.67; 95% CI, 0.55-0.82). No significant difference was observed in the likelihood of receiving adjuvant RT compared with no therapy for patients ages 75 to 80, 80 to 85, and 90 years versus patients ages 70 to 75 years.
Combined-Modality Therapy
Younger age, male gender, white race, non-Hispanic ethnicity, a lower Charlson/Deyo comorbidity score, government insurance (compared with private insurance), treatment at a community treatment facility, and later year of diagnosis were associated with an increased likelihood of receiving CRT versus receiving no adjuvant therapy (Table 1 ). An analysis of subgroups stratified by age group (ages70-75, 75-80, 80-85, 85-90, and 90 years) demonstrated that patients between ages 70 and 75 years (reference group) were most likely to receive CRT, patients in each successive age subgroup were less likely to receive CRT than those in the preceding subgroup (OR, 0.72-0.10; P < .0001 for all), and patients aged 90 years were the least likely to receive CRT (OR, 0.10; 95% CI, 0.06-0.16). Abbreviations: CRT, chemoradiation; CT, chemotherapy; LOR, lower limit of 95% confidence interval for odds ratio; OR, odds ratio; Ref, referent category; RT, radiation therapy; UOR, upper limit of 95% confidence interval for odds ratio. a Other facility type includes nonhospital-based, free-standing cancer programs offering a minimum of 1 cancer-related treatment modality, hospital-associated cancer programs that treat <100 patients with newly diagnosed malignancies per year, and Veterans Affairs programs.
Original Article
CRT Versus RT
Multivariate logistic regression was performed to identify predictors of the addition of CT to the treatment of patients who were receiving RT ( Table 2) . Patients ages 75 to 80, 80 to 85, 85 to 90, and 90 years were less likely to receive CRT than adjuvant RT alone (OR, 0.75-0.17; P < .0001 for all), and each successive age group was less likely to receive CRT than RT compared with the preceding group.
RT Fractionation
The majority of patients with RT dose information (82.4%) received standard fractionation RT, defined by a fraction size 2 grays (Gy) (Supporting Table 2 ; see online sup porting information). The most common fractionation schedule in our population approximated the protocol reported by Stupp 18 ; 0.7%), were much less common.
Survival
At the last follow-up, 94% of patients had died. The median length of follow-up was 6.2 months (range, 1-118 months), and the median OS for our entire cohort was 6.31 months (95% CI, 6.21-6.44 months) (Supporting Fig. 1 ; see online supporting information). Patients who received CRT had the greatest median OS at 9.20 months (95% CI, 8.97-9.46 months); whereas patients who received adjuvant RT alone (median OS, 5.29 months; (Table 3) .
DISCUSSION
The optimal adjuvant treatment for elderly patients with newly diagnosed GBM has not been definitively demonstrated, and there are significant differences in the treatment of these patients in the United States. We examined over 14,000 patients in the NCDB to report patterns of care and identify predictors of various adjuvant treatment strategies in this underrepresented population in the modern era. We observed an increasing trend toward the use of combined-modality treatment with CRT from 2004 to 2012 and associated combined-modality treatment with improved survival. The composite findings from our analysis support the consideration of adjuvant CRT for carefully selected elderly patients. Patients over 70 years of age were excluded from the landmark EORTC-NCIC trial published in 2005, with less than 30% of included patients over 60 years old and even fewer patients greater than 65 years of age. 6, 19 However, with the report of a survival benefit for combinedmodality therapy in younger patients, in addition to the relatively favorable toxicity profile of temozolomide, 20, 21 adjuvant CRT may have been perceived as an increasingly appealing treatment paradigm for elderly patients. Patients in our population were increasingly likely to receive combined-modality therapy over the temporal course of the study interval, perhaps reflecting the impact of the EORTC-NCIC results.
Although there is a clear trend over the study interval toward the increased use of CRT to treat these patients, their age continues to strongly predict for adjuvant therapy. The youngest patients in our study were significantly more likely to receive adjuvant therapy with CRT, CT, or RT than no adjuvant therapy compared with the oldest patients. Although patients who were diagnosed toward the later end of our interval were much more likely to receive combined-modality therapy than RT alone compared with those who were diagnosed earlier, younger patients were still more likely to receive CRT than RT alone compared with older patients despite controlling for diagnosis year. This finding is concordant with previously described treatment trends in patients with both resected and biopsied GBM. 12, 22 In addition to age, patient demographic and treatment factors, including sex, race, and treatment facility type, predict the receipt of adjuvant therapy. Patients with increasing Charlson/Deyo comorbidity scores were less likely to receive combined-modality therapy with CRT, perhaps reflective of the concern that, in addition to poorer overall prognosis, 23 elderly patients may have increased difficulties tolerating toxicity from multimodality therapy. 19, 24, 25 Multiple treatment regimens, including single-modality adjuvant therapy, that demonstrate benefit further exacerbate the difficulty of appropriately selecting adjuvant therapy for these patients. 9, 10 The lack of adverse event reporting in the NCDB limits our ability to determine whether the avoidance of multimodality therapy is warranted in this patient population.
Single-modality adjuvant therapy using either RT or CT produced a survival benefit over best supportive care in our study. However, in a multivariate analysis adjusted for patient and treatment characteristics, including age, comorbidity score, and diagnosis year, treatment with adjuvant CRT resulted in superior survival compared with singlemodality therapy. Previous investigations of institutional, 26, 27 population, 22, 28 and hospital-level data 12 support this finding. Although prospective validation will be needed to further define which elderly patients with GBM should receive adjuvant CRT, this analysis of a large cohort of elderly patients may offer support in selecting combinedmodality adjuvant therapy for elderly patients who are deemed clinically appropriate.
Defining the role of hypofractionated RT regimens in the treatment of elderly patients with GBM has been an area of active interest. Previous investigations have suggested that abbreviated schedules of RT may be considered reasonable treatment alternatives for select elderly patients. 17, 18 Most patients in our overall cohort (82.4%) received a variation of standard fractionated RT, defined by a fraction size 2 Gy. The majority of patients in our population who received adjuvant CRT (66.9%) received fractionation that mirrored the standard fractionation schedule of 60 Gy delivered in 30 fractions. Because a common clinical rationale for selecting shortened courses of RT is poorer functional status, and because patient performance status was unavailable using the NCDB registry, we believed that an evaluation of the effect of RT fractionation schedules on patient outcomes would be inappropriate for the current analysis because of limited ability to control for potential cofounders and the relatively few patients who received hypofractionated treatment. Given the mounting evidence from emerging clinical trials and hospital-level data demonstrated a benefit from combined-modality therapy, randomized clinical trials are needed to compare outcomes and quality of life between standard fraction and hypofractionated RT when combined with CT.
Although the NCDB captures and prospectively maintains a large cohort of elderly patients with primary GBM, there are distinct limitations to this study in addition to the biases inherent to retrospective, observational design. Validated prognostic factors, including patient performance status, extent of tumor resection, and molecular profiling data (including O 6 -methylguanine-DNAmethyltransferase [MGMT] promoter methylation status), were unavailable in the data. It is possible that the distribution of patients with favorable factors was not equivalent among the treatment cohorts, potentially modulating observed survival benefits. Although several demographic and treatment factors, including age, year of diagnosis, and Charlson/Deyo comorbidity score, were detailed and subsequently controlled for in our analyses, these factors likely do not fully capture the discrepancies in baseline health and health care resources for the overall cohort.
Whereas patient demographic and treatment factors, including sex, race, ethnicity, and treatment facility type, were associated with receiving adjuvant therapy, it is unclear whether these factors are simply correlated with receiving adjuvant therapy or are driving treatment disparity in this population. The influence of socioeconomic factors, including access to health care resources and the potential for distinct biologic differences (including mutational and molecular profiles in GBM), are areas of active research. [29] [30] [31] Further studies that include molecular profiling of elderly patients stratified by patient and treatment factors will be needed to validate these associations.
The NCDB collects treatment information only regarding the primary course of therapy; therefore, specifics of disease progression and treatment failure were not available. Cancer-specific survival was not collected in the database, and the potential role of salvage therapy in modifying OS could not be fully defined. The lack of granularity regarding the specific CT received as well as the limited information regarding dosing schedule are further restrictions in the data. We also are limited because only data on combined-modality treatment are included and not whether CRT was concurrent or sequential. Despite these limitations, our analysis of this large cohort of patients who received treatment at multiple institutions across the United States offers a perhaps more representative report of patterns of care and outcomes for the overall population of elderly patients who have newly diagnosed GBM than reports investigating patients who received treatment at a single institution or who were eligible for clinical trials.
Conclusions
In this analysis, we have reported patterns of care, predictors for receiving adjuvant therapy, and survival outcomes stratified by treatment paradigm for a large cohort of elderly patients with primary GBM. Although there is a clear trend in time toward the increased use of CRT to treat these patients, older patients are still less likely to receive combined-modality therapy than adjuvant RT alone or no adjuvant therapy compared with younger patients in this population. CRT demonstrated improved survival outcomes relative to single-modality therapy using either RT or CT and over no adjuvant therapy. CRT should be considered as adjuvant therapy for elderly patients with primary GBM who are deemed clinically appropriate.
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